Skip to main content

Forfatter: business

THE INTERREG. PROJECT HERINNERINGEN (‘MEMORIES’) 2018 SYMPOSIUM ON EARLY BIOMARKERS FOR SPORADIC ALZHEIMERS

27.11.2018 BY TOXGENSOLUTIONS BV
Many thanks to the participants, and especially the speakers: Catherine Verfaillie (KULeuven (host)), Francesca Pistollato (EURLECVAM (invited speaker)), Annemie Ribbens (icometrix), Sebastiaan Engelborghs (UAntwerpen), Gerard Griffioen (reMYND), Jacco Briede and Rob Schlooz (UMaastricht) and Erwin L Roggen (ToxGenSolutions).

The presentations will soon be available on toxgensolutions.eu.

TOXGENSOLUTIONS BV INVITES APPLICATIONS FOR A POSITION AS EXPERIENCED RESEARCHER, STARTING JANUARY 1, 2019.

16.11.2018 BY TOXGENSOLUTIONS BV

POSITION FOR AN EXPERIENCED RESEARCHER

ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

You see you self as a researcher at a spin-off company based at the University of Maastricht with an ambition to expand. The research field is Neurodegeneration of the human brain, with focus on Alzheimer’s Disease (AD).

The successful candidate will participate in an AD project supported by EU Interreg. Vlaanderen – Nederland, het Nederlands Ministerie van Economische Zaken, de Provincie Nederlands Limburg, Vlaams Agentschao Innoveren en Ondernemen (VLAIO) and the Provinces of Antwerpen and Vlaams Brabant.

RESPONSIBILITIES AND TASKS:

  • Experimental planning of the project, problem solving and assuring compliance with the timelines of the project.
  • Laboratory work within the field of microRNA detection.
  • Performance of differential (epi-)genomics and pathway analyses.
  • Handling and reporting of experimental data.
  • Preparing microRNA profiles with diagnostic value for the market.

QUALIFICATIONS:
Applicants should have a PhD degree in (epi)genomics or equivalent with several years of experience.

THE PROFILE OF THE IDEAL CANDIDATE:

  • You have experience with and enjoy laboratory work.
  • You have hands-on experience with state-of-the-art (epi-)genomics technologies.
  • Experience in bioinformatics will be considered an advantage.
  • You communicate fluently in English.
  • You can work with deadlines and pressure.
  • You are flexible, enthusiastic and responsible, with team spirit and excellent collaboration skills.

WE OFFER:
ToxGenSolutions BV offers a competitive scientific environment with the ambition to build a self-sustainable company applying front-edge non-animal toxicogenomics approaches on human health problems to provide the customer with genetic biomarker fingerprints for application in novel more accurate methods for diagnosis, novel tools for follow-up of disease progression or response to treatment in humans, and novel drug development.

SALARY AND TERMS OF EMPLOYMENT:
The appointment will be based on the current wage scales that are applied by the University of Maastricht. The position is for two years.

FURTHER INFORMATION:
For additional information about the position, please contact Erwin L Roggen (erwin.roggen@toxgensolutions.eu).

You can read more about ToxGenSolutions BV on www.toxgensolutions.eu.

APPLICATION PROCEDURE:
Please submit your application no later than December 10, 2018 (Local time). Applications and enclosures received after the deadline will not be considered.

Applications must be submitted as one PDF file containing all your materials in English. The file must include:

  • Application (cover letter)
  • CV
  • Diploma (MSc)

All interested candidates irrespective of age, gender, disability, race, religion or ethnic background are encouraged to apply.


YOU ARE HEREBY CORDIALLY INVITED TO THE FIRST ANNUAL MEETING ON NOVEMBER 23TH 2018 IN BUILDING ON1 AT THE KATHOLIEKE UNIVERSITY LEUVEN (HERESTRAAT 49, LEUVEN).

23.10.2018 BY TOXGENSOLUTIONS BV

The project ‘Herinneringen’ (‘Memories’) is about to finish the first year of its search for a cost-effective and minimally invasive method allowing for accurate diagnosis of (sporadic) Alzheimer’s disease (AD) before significant damage to the brain has occurred.

You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven). Participation is free but registrations via the project web site (Menu, Contact) is required for practical reasons.

The program can be downloaded from the same web site. Francesca Pistollato from the European Reference Laboratory – European Center for validation of Alternative methods to Animal Testing (EURL-ECVAM) will address the current challenges met by traditional AD research, and the need for the paradigm shift that forms the basis of the project ‘‘Herinneringen’ (‘Memories’).

The project partners will present an overview of the different activities that are planned to meet the final goal, and progress will be reported where relevant. Special attention will be given to (i) the selection of the external risk factors for sporadic AD; (ii) the cell-based methods for identification of molecular and cellular processes that may be involved in the onset and early development of AD-related processes; (iii) the strategies to scientifically validated the human relevance of the identified potential biomarkers. See you November 23th.

@TOXGENSOLUTIONS BV DISEMBARKS ON ITS DATA-DRIVEN JOURNEY TOWARDS NOVEL TOOLS AND TREATMENTS FOR IMPROVING THE QUALITY OF LIFE OF PATIENTS WITH SPORADIC #ALZHEIMERS.

February 09, 2018 @TozGenSolutions and its partners in the project #Herinneringen (”Memories”) have disembarked on their journey towards a technology platform for 1) development of a non-invasive method for early #diagnosis, 2) identification of novel #drug targets and 3) improved #drugdevelopment approaches.

The building of the platform is data-driven (as opposed to the current hypothesis-driven strategies) and based on adverse outcome pathways (#AOP) identified using #nonanimal genomics-based methods and involving cell models, and matched human clinical samples and human cohorts.

The overall objective is to break the current deadlock and to provide patients with sporadic #Alzheimers with novel tools and treatments that improve their quality of life. Every partner in the consortium (icometrix, Katholieke Universiteit Leuven, reMYND, ToxGenSolutions, Universiteit Antwerpen, Universiteit Maastricht) is based in Flanders and the Southern Netherlands and is a leader in their professional field. Bundling these strengths and the resulting synergy will serve as a great stimulus for targeted innovation. The total budget for “Memories” is €2,476,613.03.

The project will run from January 1, 2018 up to and including December 31, 2020. The budget is provided by public organizations, such as Interreg. Vlaanderen-Nederland, the Dutch Ministry of Economic Affaires, the Flemish Region and Provinces.

TOXGENSOLUTIONS BV PREPARES FOR TACKLING A GROWING HEALTH PROBLEM: DEMENTIA

#ToxGenSolutions BV is looking for funding of a cross-borders private (SMEs)/public project aiming at expanding our understanding of the early events of neurodegenerative diseases, e.g. #Alzheimers. One deliverable is a novel tool for early diagnosis of neurodegenerative diseases, e.g. Alzheimers.

The project will focus on the #animalfree identification of the molecular and cellular mechanisms triggered by a selection of relevant environmental chemicals and pharmaceuticals in human induced pluripotent stem cells (#iPSC), and iPSC-derived human brain tissue, with and without genetic mutations observed in Alzheimers patients.

Early diagnosis is the first step towards improved therapies capable of suppressing disease progression. It is also anticipated that this project allows for the identification of new targets for drug development, having an additional positive impact on the quality of therapy.

SAXOCON APS (DK) AND TOXGENSOLUTIONS BV (NL) JOIN FORCES TO IMPROVE #ANIMALFREE PRODUCT DEVELOPMENT

(Q)SAR modeling is currently used to identify chemicals having desired physico-chemical/structural characteristics (e.g. new leads for drug development), or exhibiting characteristics known to exert adverse effects in humans (e.g. hazard identification and safety testing).

It is not well established yet how well these (Q)SAR models discriminate chemicals with similar physico-chemical/structural characteristics but different in vivooutcome. This is a problem e.g. when in vivo animal models incorrectly indicate unsatisfactory efficacy or toxicity.

By combining physico-chemical/structural analysis [Saxocon ApS (DK)] and biological pathway analysis of exposed human cells and tissue [ToxGenSolutions BV (NL)], both companies are convinced that they can offer costumers a novel quantitative #animalfree systems biology approach for efficacy/toxicity assessment, and more accurate human health and safety, where current in vivo animal models fail.

APPLICATION NR. 14/028.308 ‘IN VITRO METHOD FOR DETERMINING IMMUNOTOXICITY OF A COMPOUND’ IS NOW ALSO ALLOWED FOR ISSUANCE AS A PATENT IN THE USA

Main claim:
An in vitro method of detecting altered expression of at least one marker gene in response to a compound, the method comprising: – exposing a nucleated cell to the compound; – detecting the level of the at least one marker gene expressed by the nucleated cell after exposure to the compound; and – detecting altered expression of the at least one marker gene if the level of expression of the at least one marker gene is above or below a predetermined reference value for the level of expression of the at least one marker gene; – wherein the at least one marker gene is selected from the group consisting of ABCA1, CHAC1, CRIM1 and HMGCS1; and – wherein the immunotoxicity of the compound is not known.

EPO HAS GRANTED A EUROPEAN PATENT ON THE BASIS OF THE APPLICATION 12 184 575.4-1402 ”IN VITRO METHOD FOR DETERMINING IMMUNOTOXICITY OF A COMPOUND”

Claim 1:In vitro method for determining whether a compound is immunotoxic wherein the expression level of at least one marker gene is determined in a sample obtained from a Jurkat cell culture in vitro, which is exposed to the compound in the in vitro culture, wherein the marker gene is ABCA1, and wherein it is concluded that the compound is immunotoxic if the expression level of the ABCA1 marker gene is below or above a predetermined reference value. 

Claim 2: Method according to claim 1 wherein the expression level of three additional marker genes is determined in the sample obtained from the Jurkat cell cultured in vitro wherein it is concluded that the compound is immunotoxic if the expression level of at least one additional marker gene is below or above a predetermined reference value wherein the additional marker genes are CHAC1, CRIM1 and HMGCS1.